Meeting
2020 ASCO Virtual Scientific Program
First-in-human phase Ib study of ATRC-101, an engineered version of a patient-derived antibody targeting a tumor-restricted ribonucleoprotein complex.
Authors
Jonathan Eliot Benjamin
Atreca, Inc., South San Francisco, CA
Jonathan Eliot Benjamin , Nicholas Higgins , Carl Millward , Jeff Defalco , Amy Manning-Bog , Iraz T Aydin , Danhui Zhang , Shaun Lippow , Alexander Scholz , Yvonne Leung , Yanhong Zhu , Anna Sedello , Zane Rogers , Ish Dhawan , Daniel Emerling , William H. Robinson , Tito Serafini , Norman Greenberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
New Targets and New Technologies (IO)
Clinical Trial Registration Number
NCT04244552
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS3168)
DOI
10.1200/JCO.2020.38.15_suppl.TPS3168
Abstract #
TPS3168
Poster Bd #
232
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
ADU-1604, a novel CTLA-4 blocking antibody, to modulate pharmacodynamic markers in patients with PD1 relapse/refractory melanoma.
First Author: Guillermo De Velasco
Poster
2023 ASCO Annual Meeting
Safety and efficacy of Sleeping Beauty TCR-T cells targeting shared KRAS and TP53 mutations expressed by solid tumors in first-in-human phase 1 study.
First Author: Maria Pia Morelli
Poster
2023 ASCO Gastrointestinal Cancers Symposium
RELATIVITY-106: A phase 1/2 trial of nivolumab (NIVO) + relatlimab (RELA) in combination with bevacizumab (BEV) in first-line (1L) hepatocellular carcinoma (HCC).
First Author: Bruno Sangro
Poster
2022 ASCO Annual Meeting
Characterization of tumor antigen expression and myeloid immune profiles to inform the development of immune stimulating antibody conjugates (ISACs).
First Author: Lisa K. Blum